The metered dose inhalers market was valued at $10,081.4 million in 2024 and is estimated to reach $18,406.27 million by 2034, exhibiting a CAGR of 6.2% from 2025 to 2034.
A Metered Dose Inhaler (MDI) is a device commonly used to deliver medications directly to the lungs, primarily for conditions like asthma, COPD (chronic obstructive pulmonary disease), and other respiratory disorders. These inhalers consist of a pressurized canister containing medication, which is released through a mouthpiece when the canister is actuated. The medication is usually in the form of an aerosol or suspension that is inhaled during a breath, ensuring rapid absorption in the lungs. MDIs are widely preferred due to their compact design, ease of use, and ability to provide quick relief from symptoms like wheezing, coughing, and shortness of breath. In recent years, advances such as dose counters, breath-actuated mechanisms, and environmentally friendly propellants have enhanced the effectiveness and safety of MDIs. They play a critical role in both emergency and maintenance therapy for millions of patients worldwide, particularly in outpatient and home care settings.
Rise in aging population, improved compliance, environmental regulations, and generic availability are fueling steady growth in the global metered dose inhalers market. Moreover, initiatives taken by key industry players are further contributing to the market’s positive trajectory. For instance, in January 2023, the Hormosan Pharma GmbH (Hormosan), Lupin’s wholly-owned subsidiary in Germany, announced the launch of Luforbec 100/6 (beclometasone 100µg / for moterol 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.
Moreover, to reduce the environmental impact of inhalers, pharmaceutical companies are transitioning to low-global warming potential (GWP) propellants. For instance, Kindeva Drug Delivery is set to produce MDIs using propellants like HFA-152a and HFO-1234ze, which offer GWP reductions of up to 90% and 99.9%, respectively, compared to the traditional HFA-134a . In addition, artificial Intelligence (AI) is being utilized to optimize drug delivery. Machine learning algorithms analyze factors such as breathing profiles and disease status to adjust inhaler settings, ensuring targeted drug release to specific lung sites while minimizing side effects. With companies actively developing new formulations and expanding their product portfolios, the metered dose inhalers market is expected to continue witnessing robust growth in the coming years.
Segment Overview:
The metered dose inhalers market is segmented on the basis of product type, application, distribution channel, and region. On the basis of product type the market is segmented into conventional MDIs, and breath-actuated MDIs. On the basis of application, the market is segmented into asthma, COPD and others. On the basis of distribution channel, the market is fragmented into hospital pharmacies, retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
The major key players that operate in the global metered dose inhalers market are AstraZeneca, GlaxoSmithKline Pharmaceuticals Ltd, Chiesi Farmaceutici S.p.A., Cipla Ltd., Teva Pharmaceutical Industries, Lupin, AptarGroup, Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., and Zydus Lifesciences Limited.
Key Market Segments
By Application
Asthma
COPD
Other
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Product Type
Conventional MDIs
Breath actuated MDIs
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
AstraZeneca
Cipla Ltd.
Teva Pharmaceutical Industries
Lupin
Boehringer Ingelheim International GmbH
Zydus Lifesciences Limited
Chiesi Farmaceutici S.p.A.
GlaxoSmithKline Pharmaceuticals Ltd
AptarGroup, Inc.
Sun Pharmaceutical Industries Ltd.The research methodology of the global market involves extensive primary and secondary research. Primary research includes about over 12 hours of interviews and discussion with a wide range of stakeholders, including upstream and downstream participants. The primary research typically is the bulk of our research efforts; however, coherently supported by extensive secondary research. Researchers have reviewed over 6,765 product literatures, industry releases, annual reports, and other such documents of key industry participants to obtain better market understanding and gain competitive intelligence. In addition, authentic industry journals, trade associations' releases,and government websites have also been reviewed for generating high-value industry insights.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increase in prevalence of respiratory diseases
- 3.4.1.2. Availability of generic and low-cost inhalers
- 3.4.1.3. Technological advancements in metered dose inhalers
- 3.4.2. Restraints
- 3.4.2.1. Challenges in Patient Awareness and Regulatory Approvals
- 3.4.3. Opportunities
- 3.4.3.1. Development of eco-friendly inhalers
- CHAPTER 4: METERED DOSE INHALERS MARKET, BY PRODUCT TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Conventional MDIs
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Breath actuated MDIs
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: METERED DOSE INHALERS MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Asthma
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. COPD
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Other
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- CHAPTER 6: METERED DOSE INHALERS MARKET, BY DISTRIBUTION CHANNEL
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Online Pharmacies
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- CHAPTER 7: METERED DOSE INHALERS MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Product Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Product Type
- 7.2.5.1.2. Market size and forecast, by Application
- 7.2.5.1.3. Market size and forecast, by Distribution Channel
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Product Type
- 7.2.5.2.2. Market size and forecast, by Application
- 7.2.5.2.3. Market size and forecast, by Distribution Channel
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Product Type
- 7.2.5.3.2. Market size and forecast, by Application
- 7.2.5.3.3. Market size and forecast, by Distribution Channel
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Product Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Product Type
- 7.3.5.1.2. Market size and forecast, by Application
- 7.3.5.1.3. Market size and forecast, by Distribution Channel
- 7.3.5.2. France
- 7.3.5.2.1. Market size and forecast, by Product Type
- 7.3.5.2.2. Market size and forecast, by Application
- 7.3.5.2.3. Market size and forecast, by Distribution Channel
- 7.3.5.3. UK
- 7.3.5.3.1. Market size and forecast, by Product Type
- 7.3.5.3.2. Market size and forecast, by Application
- 7.3.5.3.3. Market size and forecast, by Distribution Channel
- 7.3.5.4. Italy
- 7.3.5.4.1. Market size and forecast, by Product Type
- 7.3.5.4.2. Market size and forecast, by Application
- 7.3.5.4.3. Market size and forecast, by Distribution Channel
- 7.3.5.5. Spain
- 7.3.5.5.1. Market size and forecast, by Product Type
- 7.3.5.5.2. Market size and forecast, by Application
- 7.3.5.5.3. Market size and forecast, by Distribution Channel
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Product Type
- 7.3.5.6.2. Market size and forecast, by Application
- 7.3.5.6.3. Market size and forecast, by Distribution Channel
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Product Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. Japan
- 7.4.5.1.1. Market size and forecast, by Product Type
- 7.4.5.1.2. Market size and forecast, by Application
- 7.4.5.1.3. Market size and forecast, by Distribution Channel
- 7.4.5.2. China
- 7.4.5.2.1. Market size and forecast, by Product Type
- 7.4.5.2.2. Market size and forecast, by Application
- 7.4.5.2.3. Market size and forecast, by Distribution Channel
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Product Type
- 7.4.5.3.2. Market size and forecast, by Application
- 7.4.5.3.3. Market size and forecast, by Distribution Channel
- 7.4.5.4. Australia
- 7.4.5.4.1. Market size and forecast, by Product Type
- 7.4.5.4.2. Market size and forecast, by Application
- 7.4.5.4.3. Market size and forecast, by Distribution Channel
- 7.4.5.5. South Korea
- 7.4.5.5.1. Market size and forecast, by Product Type
- 7.4.5.5.2. Market size and forecast, by Application
- 7.4.5.5.3. Market size and forecast, by Distribution Channel
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Product Type
- 7.4.5.6.2. Market size and forecast, by Application
- 7.4.5.6.3. Market size and forecast, by Distribution Channel
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Product Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Product Type
- 7.5.5.1.2. Market size and forecast, by Application
- 7.5.5.1.3. Market size and forecast, by Distribution Channel
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Product Type
- 7.5.5.2.2. Market size and forecast, by Application
- 7.5.5.2.3. Market size and forecast, by Distribution Channel
- 7.5.5.3. South Africa
- 7.5.5.3.1. Market size and forecast, by Product Type
- 7.5.5.3.2. Market size and forecast, by Application
- 7.5.5.3.3. Market size and forecast, by Distribution Channel
- 7.5.5.4. Rest of LAMEA
- 7.5.5.4.1. Market size and forecast, by Product Type
- 7.5.5.4.2. Market size and forecast, by Application
- 7.5.5.4.3. Market size and forecast, by Distribution Channel
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2024
- CHAPTER 9: COMPANY PROFILES
- 9.1. AstraZeneca
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
- 9.2. GlaxoSmithKline Pharmaceuticals Ltd
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.3. Chiesi Farmaceutici S.p.A.
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.4. Cipla Ltd.
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
- 9.5. Teva Pharmaceutical Industries
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
- 9.6. Lupin
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
- 9.7. AptarGroup, Inc.
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
- 9.8. Boehringer Ingelheim International GmbH
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
- 9.9. Sun Pharmaceutical Industries Ltd.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
- 9.10. Zydus Lifesciences Limited
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook